Harvard Bioscience (HBIO) Short term Debt (2016 - 2025)
Harvard Bioscience (HBIO) has disclosed Short term Debt for 13 consecutive years, with $34.0 million as the latest value for Q3 2025.
- Quarterly Short term Debt rose 841.96% to $34.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $34.0 million through Sep 2025, up 841.96% year-over-year, with the annual reading at $37.0 million for FY2024, 530.76% up from the prior year.
- Short term Debt for Q3 2025 was $34.0 million at Harvard Bioscience, down from $34.9 million in the prior quarter.
- The five-year high for Short term Debt was $37.0 million in Q4 2024, with the low at $2.0 million in Q1 2021.
- Average Short term Debt over 5 years is $10.0 million, with a median of $3.5 million recorded in 2023.
- The sharpest move saw Short term Debt decreased 29.82% in 2021, then surged 866.61% in 2025.
- Over 5 years, Short term Debt stood at $3.2 million in 2021, then grew by 17.81% to $3.8 million in 2022, then skyrocketed by 53.74% to $5.9 million in 2023, then skyrocketed by 530.76% to $37.0 million in 2024, then fell by 8.09% to $34.0 million in 2025.
- According to Business Quant data, Short term Debt over the past three periods came in at $34.0 million, $34.9 million, and $36.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.